SPECIAL FEATURES

CCR Translations

323

BAP1tism of a Tumor Suppressor
Scott E. Woodman
See article p. 408

Molecular Pathways

326

Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
William C. Dougall

Perspective

336

New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

Review

342

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan and Irene M. Ghobrial

HUMAN CANCER BIOLOGY

350

Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Brooke E. Sylvester, Dezheg Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

360

A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Rajusubramaniam Shanmugam, Padmaja Gade, Annique Wilson-Weekes, Hamid Sayar, Attaya Suvarnasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and H. Scott Boswell

370

Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Rossitza Lazova, Robert L. Camp, Vincent Klump, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

380

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Hui-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osaisuke Iwano, Takao Yaotora, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

392

Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Oriti, Shioshi Nishise, Ko Nagino, Daisuke Iwano, Takao Yaotora, Kazuya Yoshizawa, Hideki Saito, Yasuhisa Tanaka, and Sumio Kawata

400

Lifetime Cancer Risks in Individuals with Germine $P T E N$ Mutations
Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

CANCER THERAPY: PRECLINICAL

408

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour
See commentary p. 323

417

Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
Sascha Dietrich, Oliver H. Kramer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Tretter, Michael Rieger, Jennifer Hullein, Thorsten Zenz, Anthony D. Ho, Peter Dregger, and Thomas Luft
432 Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

442 Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer
Audrey Cras, Beatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

454 Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
Andreas Wicki, Christoph Buchlitz, Annette Orleth, Reto Ritschard, Inke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot

465 EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi, Jorge Dorado, Patrick A. Baeuerle, and Christopher Heeschen

475 CPTH6, a Thiazole Derivative, Induces Histone Hypoaetylation and Apoptosis in Human Leukemia Cells
Daniela Trisciuoglio, Elena Ragazzoni, Andrea Pelosi, Marianna Desideri, Simone Carra, Chiara Gubelli, Giovanna Maresca, Riccardo Nescatelli, Daniela Secchi, Adriana Bolognese, Bruna Bizzarri, Chiara Cavalliere, Igea D’Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo

487 Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

499 VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu, Gregory N. Dietrich, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffrey Howbert, Mary L. Disis, and Robert M. Hershberg

510 Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

IMAGING, DIAGNOSIS, PROGNOSIS

524 Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
Jhi-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petri, Quyan Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone

534 MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

546 Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Harry H. Yoon, Qian Shi, William R. Sukov, Anne E. Wiktor, Malika Khan, Christopher A. Sattler, Axel Grothey, Tsung-Teh Wu, Robert B. Diasio, Robert B. Jenkins, and Frank A. Sinicrope

CANCER THERAPY: CLINICAL

555 Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Josman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazzula, Karin Kemsley, and Reinhard Dummer
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, and Gary K. Schwartz

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.